At its meeting on 22 May 2023, the Transparency Council adopted Opinion No. 103/2023 on the appropriateness of amending Part B of the drug programme B.70 “Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)”, i.e. “Treatment of patients with diabetic macular oedema (DME)”.